Physician profile
Ashley Blake Studnik
NPI 1508638990
$4,378.94
in general payments reported to CMS, 2019-2025
25 companies · $2,811 in 2025
The $2,811 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $18.40 · 2024: $1,550 · 2025: $2,811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,279 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,278.95 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $681.74 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $430.48 | 2024-2025 | |
| Incyte Corporation | $424.34 | 2024-2025 | Opzelura |
| Genzyme Corporation | $414.80 | 2024-2025 | |
| Abbvie INC. | $336.74 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $285.66 | 2024-2025 | |
| Arcutis Biotherapeutics, INC. | $237.90 | 2024-2025 | Zoryve |
| Ucb, INC. | $215.22 | 2024-2025 | Bimzelx |
| Lilly USA, LLC | $197.97 | 2024-2025 | Taltz, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $184.13 | 2024-2025 | Jublia, Cabtreo, Arazlo |
| Organon LLC | $161.51 | 2025 | Vtama |
| Regeneron Healthcare Solutions, INC. | $142.63 | 2024-2025 | Dupixent, Libtayo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $120.48 | 2024-2025 | Spevigo |
| Revance Therapeutics, INC. | $92.51 | 2025 | Daxxify |
| Mayne Pharma Commercial LLC | $73.72 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $73.23 | 2024-2025 | Adbry |
| Galderma Laboratories, L.P. | $60.17 | 2025 | Nemluvio, Aklief |
| Botanix Sb INC | $58.27 | 2025 | Sofdra |
| Journey Medical Corporation | $44.34 | 2025 | |
| Biofrontera INC. | $42.05 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Almirall LLC | $31.03 | 2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $22.56 | 2024 | Ycanth |
| Mindera Corp | $18.39 | 2025 | |
| Solta Medical, A Division of Bausch Health US, LLC | $14.76 | 2024 | Clear+Brilliant |
| Tempus Ai, INC | $14.31 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Studnik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.